FSD Pharma Inc, (CSE:HUGE), a licensed producer under the Cannabis Act, today provided a corporate update on operations, strategy and leadership changes.

Management Changes


On February 6, 2019, the Company announced it had implemented changes in leadership and business practices to optimize operations. Accordingly, the Company announced that Dr. Raza Bokhari, Executive Co-Chairman, has been appointed interim Chief Executive Officer of FSD Pharma.

“It is with great pleasure that I return to the role of the interim CEO at such a momentous time for the company,” said Dr. Raza Bokhari, Executive Co-chairman & interim CEO.

Operational Update

To optimize operations, FSD’s Board of Directors terminated a definitive agreement with Auxly Cannabis Group Inc. (“Auxly”) on February 6th, 2019. FSD believes that Auxly was under clear obligation to develop all aspects of the company’s cannabis cultivation facility in mutually agreed upon staged phases. Auxly had made commitments anticipating that the first phase of construction would be completed and ready for Health Canada approval by the end of December 2018 which never materialized.

“We have unique and valuable assets poised to unlock sustainable shareholder value and reenergize execution of our company’s founding vision and mission,” said Dr. Raza Bokhari. “Our work is guided by our drive and passion to capitalize on the opportunities before us and ensure that our efforts serve the strategic and operational goals of the business, our employees and our shareholders.”

Dr. Raza Bokhari continued: “We have a clear plan moving forward to build a global retail and medicinal cannabis footprint. We intend to continue our 220,000 phase 1 building expansion and are assessing different opportunities with other potential strategic partners and construction companies including utilizing our cash, securities and other assets  on hand to continue progressing forward. We will update investors as soon as possible and only upon signing of definitive agreements. We will continue to optimize our 25,000 square foot licensed cultivation area adding high value varietals, while utilizing best practices in the latest agricultural science. We are making good progress with the much-anticipated sales license and we have a strong cash and asset position with no debt.

Strategic Partnerships

In 2018, FSD has made strategic investments totaling CDN $8 million in Cannara Biotech, SciCann Therapeutics (“SciCann”), Hightide Ventures, Huge Shops, and Pharmastrip Corp (“Pharmastrip”). These investments have quickly grown to nearly CDN $25 million as per current market value. Additionally, FSD recently signed royalty agreements with Canntab Therapeutics, Pharmastrip, World Class Extractions Inc., SciCann, and Solarvest BioEnergy Inc. which FSD expects to pay dividends over time.

“Acquisition of a platform company to advance R&D of synthetic and biosynthetic cannabinoids to commercial FDA approved drugs worldwide remains our ‘flagship’ strategy,” said Dr. Raza Bokhari. “We are confident that we will soon identify a suitable and compelling platform to execute on our strategic intent. We were disappointed that the intended acquisition of Therapix Biosciences did not materialize but are at the cusp of unlocking tremendous opportunities for the FDA approved application of synthetic and biosynthetic cannabinoids to address a variety of unmet needs in diseases of the central nervous system, sleep disorders, skin conditions, and to generate alternative treatment options to opioid based therapies.”

Shareholder Update

Shareholders of FSD Pharma met in a special meeting on January 22nd, 2019 and authorized the Board of Directors to consolidate class B shares and take additional steps that will enable the company to list on a major US securities exchange. The FSD Pharma Board is actively engaged in evaluating the appropriate exchange and the optimum time to do so.

The Company believes these are transformational times for the medicinal cannabis industry and for FSD Pharma shareholders, employees, and stakeholders.

“My top priority is to focus on delivering sustainable and positive shareholder value that can withstand the test of time,” said Dr. Raza Bokhari. “To achieve this, we must strengthen our leadership team with gathering world class experience, expand our board with independent members and incorporate gender and cultural diversity in all of our ranks.”

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet available for production at its Ontario facility with an additional 220,000 square feet currently in development (with an estimated cost of $250 per square foot to be completed in 2019).

FSD facilities sit on 70 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017. FV Pharma’s vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the company’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

For further information: Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc., Email:zeeshan@fsdpharma.com, Telephone: (416) 854-8884; Investor Relations: Email: IR@fsdpharma.com, Website: www.fsdpharma.com; Media Relations: Nic Johnson / Caroline Cunningham, Email: Nic.Johnson@russopartnersllc.com / Caroline.Cunningham@russopartnersllc.com, Tel: (212) 845-4242 / (212) 845-4292

Click here to connect with FSD Pharma Inc, (CSE:HUGE) for an Investor Presentation. 

Source: www.newswire.ca

Better Plant Sciences Inc. (CSE:PLNT)(OTCQB:VEGGF)(FSE:YG3) (“Better Plant” or the “Company”), a wellness company that develops and sells sustainable, plant-based products that are better for health and better for the earth, is pleased to announce that it has added The Organic Grocer to its list of retail wholesalers for Jusu Wellness and Jusu Bar products. The Organic Grocer is one of Metro Vancouver’s leading independent organic grocers, providing full service industry leading expertise in health and wellness for its community with a focus on environmental and ecological consciousness

Keep reading... Show less

Gage Growth (CSE:GAGE) CEO Fabian Monaco talks about the company’s latest merger and acquisition partnership with TerrAscend (CSE:TER,OTCQX:TRSSF) and how its different streams of revenue are driving Gage’s exponential growth within the cannabis landscape. 

“In 2021, we really hit the ground running, just like we’re going to hit 2022 running even faster. We had phenomenal growth, quarter-over-quarter growth, and we’re looking to expand quite exponentially as we approach the year 2022 in Michigan,” Monaco said.

Gage entered into a US$545 million definitive arrangement agreement with TerrAscend wherein shareholders of Gage will receive 0.3001 of a common share of TerrAscend for each Gage Share.

This CEO Interview is brought to you by:

Gage Growth (CSE GAGE) is a premier cannabis cultivator, retailer and brand in Michigan that operates on the idea that “good is just not good enough.” Its core values of providing premium cannabis to market, positively shaping cannabis culture and nurturing the community primes the company for success and rapid economic growth.Send me an Investor Kit

The combined business will have operations in five states and in Canada, including seven cultivation and processing facilities and 23 operating dispensaries serving both medical and adult-use cannabis markets in the US and Canada.

Part of the company’s plan for expansion is to bring the phenomenal Cookies brand to Canada. It will be available exclusively in Ontario via the Ontario Cannabis Store, the largest purchaser of cannabis in the world.

“We’re going to bring the Cookies brand to Canada very, very soon. We plan on opening a retail store in Canada and be the first ever Cookies-branded retail store,” said Monaco. 

Watch the full interview with Gage Growth CEO Fabian Monaco above. 

Keep reading... Show less

Specialist Investment Company, MMJ Group Holdings Limited (ASX: MMJ) (“MMJ”), wishes to advise that BevCanna Enterprises Inc.(CSE:BEV) (“BEV” or “BevCanna”) has announced an offer (the Offer) to acquire 100% of Embark Health Inc. (“Embark”). MMJ’s investment in Embark consists of shares and warrants with a current book value of CAD2.4m.

Subject to a review of the Offer documentation, MMJ expects that its share of the Initial Consideration (refer below) would approximate the current book value of MMJ’s investment1.

Keep reading... Show less

Spyder Cannabis Inc. (TSXV:SPDR) (“Spyder” or the “Company“), an established Canadian cannabis and vape retailer, is pleased to announce that its specialty vape retail brand, 180 Smoke, has entered into a strategic supplier agreement with Yi Hao Ji (Canada) Ltd. (“Yi Hao Ji“) to offer RELX closed-pod vaping products across its corporate and franchise stores, e-commerce and wholesale channels.

The closed-pod system is one of the fastest-growing sectors in the vaping vertical. More specifically, in Canada closed vaping systems have a compounded annual growth rate of 25% between 2019 and 2024 and currently account for 44% of all vape-related sales in Canada as compared to 4% prior to 2019[1].

Keep reading... Show less

New High-Tech Hardware System to Launch in 16 States by Year End

– Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the release of Cliq by Select, a breakthrough hardware system from its Select brand designed to significantly upgrade the consumer’s vaping experience. Cliq is the culmination of years of research and development to create the perfect marriage of Select’s award-winning cannabis oil with a new, intelligently designed delivery system. This new hardware will debut at Hall of Flowers today and launch in Oregon California and Arizona next week. The hardware will then continue to roll-out nationwide in states such as Massachusetts Colorado Florida Maryland Michigan Nevada New York Connecticut Maine Utah Ohio and Pennsylvania .

Keep reading... Show less